{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:24:27Z","timestamp":1791617067282,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"48","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient-level data from randomized, placebo-controlled FCM trials including adults with HF and iron deficiency with \u226552 weeks follow-up were analysed. The co-primary efficacy endpoints were (i) composite of total\/recurrent cardiovascular hospitalizations and cardiovascular death and (ii) composite of total HF hospitalizations and cardiovascular death, through 52 weeks. Key secondary endpoints included individual composite endpoint components. Event rates were analysed using a negative binomial model. Treatment-emergent adverse events were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three FCM trials with a total of 4501 patients were included. Ferric carboxymaltose was associated with a significantly reduced risk of co-primary endpoint 1 (rate ratio 0.86; 95% confidence interval 0.75\u20130.98; P = .029; Cochran Q: 0.008), with a trend towards a reduction of co-primary endpoint 2 (rate ratio 0.87; 95% confidence interval 0.75\u20131.01; P = .076; Cochran Q: 0.024). Treatment effects appeared to result from reduced hospitalization rates, not improved survival. Treatment appeared to have a good safety profile and was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad586","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T20:07:50Z","timestamp":1692907670000},"page":"5077-5091","source":"Crossref","is-referenced-by-count":125,"title":["Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-7064","authenticated-orcid":false,"given":"Piotr","family":"Ponikowski","sequence":"first","affiliation":[{"name":"Institute for Heart Diseases, Wroclaw Medical University , Wroclaw , Poland"},{"name":"Institute for Heart Diseases, University Hospital , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3222-1719","authenticated-orcid":false,"given":"Robert J","family":"Mentz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine , Durham, NC, USA"},{"name":"Duke Clinical Research Institute , Duke University Medical Center, Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Duke University Medical Center, Durham, NC , USA"},{"name":"Department of Medicine, Duke University , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX , USA"},{"name":"Department of Medicine, University of Mississippi , Jackson, MS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-7935","authenticated-orcid":false,"given":"Dirk J","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Roubert","sequence":"additional","affiliation":[{"name":"Research, Development, and Sciences, CSL Vifor , Glattbrugg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blackman","sequence":"additional","affiliation":[{"name":"Quantitative Sciences, American Regent, Inc. , Shirley, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7441","authenticated-orcid":false,"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics and DZHK (German Center for Cardiovascular Research), Partner Site G\u00f6ttingen, University Medical Center G\u00f6ttingen , G\u00f6ttingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-432X","authenticated-orcid":false,"given":"Ewa A","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute for Heart Diseases, Wroclaw Medical University , Wroclaw , Poland"},{"name":"Institute for Heart Diseases, University Hospital , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"2023122108065768000_ehad586-B1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The burden of iron deficiency in heart failure: therapeutic approach","volume":"71","author":"Rocha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023122108065768000_ehad586-B2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11739-020-02434-9","article-title":"Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting","volume":"16","author":"Marchi","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2023122108065768000_ehad586-B3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","article-title":"Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure","volume":"17","author":"Jankowska","year":"2011","journal-title":"J Card Fail"},{"key":"2023122108065768000_ehad586-B4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int J Cardiol"},{"key":"2023122108065768000_ehad586-B5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"2023122108065768000_ehad586-B6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2023122108065768000_ehad586-B7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2023122108065768000_ehad586-B8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2023122108065768000_ehad586-B9","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2023122108065768000_ehad586-B10","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023122108065768000_ehad586-B11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023122108065768000_ehad586-B12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5694\/mja2.51656","article-title":"Consensus statement on the current pharmacological prevention and management of heart failure","volume":"217","author":"Sindone","year":"2022","journal-title":"Med J Aust"},{"key":"2023122108065768000_ehad586-B13","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2023122108065768000_ehad586-B14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2023122108065768000_ehad586-B15","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2023122108065768000_ehad586-B16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2023122108065768000_ehad586-B17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1037\/a0015565","article-title":"The relative benefits of meta-analysis conducted with individual participant data versus aggregated data","volume":"14","author":"Cooper","year":"2009","journal-title":"Psychol Methods"},{"key":"2023122108065768000_ehad586-B18","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"2023122108065768000_ehad586-B19","first-page":"e13721","article-title":"Iron deficiency anemia as a rare risk factor for recurrent pulmonary embolism and deep vein thrombosis","volume":"13","author":"Ezeh","year":"2021","journal-title":"Cureus"},{"key":"2023122108065768000_ehad586-B20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B21","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","article-title":"Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency","volume":"139","author":"Charles-Edwards","year":"2019","journal-title":"Circulation"},{"key":"2023122108065768000_ehad586-B22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cvr\/cvab317","article-title":"High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis","volume":"119","author":"Petrie","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2023122108065768000_ehad586-B23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc B Stat Methodol"},{"key":"2023122108065768000_ehad586-B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1217","article-title":"Meta-analysis of few small studies in orphan diseases","volume":"8","author":"Friede","year":"2017","journal-title":"Res Synth Methods"},{"key":"2023122108065768000_ehad586-B25","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ejhf.2630","article-title":"Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B26","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ejhf.2860","article-title":"Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.122.060757","article-title":"Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: an AFFIRM-AHF subgroup analysis","volume":"147","author":"Filippatos","year":"2023","journal-title":"Circulation"},{"key":"2023122108065768000_ehad586-B28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","article-title":"Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial","volume":"15","author":"Filippatos","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023122108065768000_ehad586-B30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023122108065768000_ehad586-B31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B32","first-page":"116","article-title":"Effects of intravenous iron replacement therapy on cardiovascular outcomes in patients with heart failure: a systematic review and meta-analysis","volume":"10","author":"Reinhold","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2023122108065768000_ehad586-B33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00392-023-02207-2","article-title":"Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis","volume":"112","author":"Vukadinovi\u0107","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2023122108065768000_ehad586-B34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ejhf.2036","article-title":"High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality","volume":"23","author":"Sierpinski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023122108065768000_ehad586-B35","doi-asserted-by":"crossref","first-page":"e004519","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients","volume":"11","author":"Beverborg N","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2023122108065768000_ehad586-B36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2011.08.006","article-title":"Myocardial iron homeostasis in advanced chronic heart failure patients","volume":"159","author":"Leszek","year":"2012","journal-title":"Int J Cardiol"},{"key":"2023122108065768000_ehad586-B37","doi-asserted-by":"crossref","first-page":"mfab021","DOI":"10.1093\/mtomcs\/mfab021","article-title":"Chemistry and biology of ferritin","volume":"13","author":"Plays","year":"2021","journal-title":"Metallomics"},{"key":"2023122108065768000_ehad586-B38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2008.08.001","article-title":"Ferritin for the clinician","volume":"23","author":"Knovich","year":"2009","journal-title":"Blood Rev"},{"key":"2023122108065768000_ehad586-B39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2023122108065768000_ehad586-B40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jchf.2021.04.005","article-title":"Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy","volume":"9","author":"Jhund","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehad586\/51267907\/ehad586.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/48\/5077\/54585333\/ehad586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/48\/5077\/54585333\/ehad586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:34:24Z","timestamp":1703133264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/48\/5077\/7251520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":40,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2023,8,26]]},"published-print":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad586","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,21]]},"published":{"date-parts":[[2023,8,26]]}}}